The primary analysis of the EORTC 1333/PEACE-3 study demonstrated that enzalutamide plus radium-223 (Ra223) improved radiological progression-free survival (rPFS) compared to enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint was rPFS while overall survival (OS) was a key secondary endpoint. Interim overall survival (OS) results were reported at time of primary analysis. Here, we report…
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.
Annals of Oncology | | S. Gillessen, E. Gallardo, A. Choudhury, F. Saad, A. Soares, Y. Loriot, R. McDermott, A. Rodriguez-Vida, P. Isaacsson Velho, F. Nolè, F. Cruz, T. Roumeguere, G. Daugaard, R. Yamamura, E. Bompas, P. Maroto, F.Gomez Veiga, I. Skoneczna, K. Martins da Trindade, F. Mavignier Carcano, F. Lecouvet, C. Coens, C. Poncet, B. Fournier, B. Tombal
Topics: prostate-cancer, blood-cancer, clinical-trials, research